PTC Therapeutics, Inc. Debt/Assets

Debt/Assets of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.

Highlights and Quick Summary

  • Debt/Assets for the quarter ending June 29, 2021 was 60.51% (a 3.74% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Assets increased by 22.42%
  • Annual Debt/Assets for 2020 was 19.07% (a -5.59% decrease from previous year)
  • Annual Debt/Assets for 2019 was 20.2% (a 47.77% increase from previous year)
  • Annual Debt/Assets for 2018 was 13.67% (a -63.04% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of PTC Therapeutics, Inc.

Most recent Debt/Assetsof PTCT including historical data for past 10 years.

Interactive Chart of Debt/Assets of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 60.51% 58.33%
2020 19.07% 49.43% 25.19% 20.35% 19.07%
2019 19.33% 19.08% 12.05% 12.08% 20.2%
2018 13.67% 14.67% 29.09% 38.71% 13.67%
2017 37.02% 38.91% 36.87% 40.18% 36.99%
2016 36.46% 33.6% 31.07% 27.85% 36.43%
2015 25.14% 23.53% 0.0% 0.0% 25.14%
2014 0.0% 0.0% 0.0% 0.0% 0.0%
2013 0.03% 0.05% 1.57% 6.4% 0.03%
2012 37.35% 0.0% 0.0% 0.0% 37.35%
2011 26.44% 26.48%

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.